Reported Saturday, Genmab's Epcoritamab Monotherapy Achieves 67% ORR And 58% CR Rate While Combination With R-Mini-CHOP Delivers 93% ORR And 86% CR In Elderly Newly Diagnosed DLBCL Patients

Loading news article.

Reported Saturday, Genmab's Epcoritamab Monotherapy Achieves 67% ORR And 58% CR Rate While Combination With R-Mini-CHOP Delivers 93% ORR And 86% CR In Elderly Newly Diagnosed DLBCL Patients | WAPE

Reported Saturday, Genmab's Epcoritamab Monotherapy Achieves 67% ORR And 58% CR Rate While Combination With R-Mini-CHOP Delivers 93% ORR And 86% CR In Elderly Newly Diagnosed DLBCL Patients

Article summary

Related companies

Comments —